Several studies have reported autoantibody production being induced by COVID-19 infection though we still do not understand their full spectrum. This work reinforces the idea that a COVID-19 infection may trigger serious autoimmune disease, “suggesting that this occurs against multiple molecules with key functions in immune and vascular homeostasis such as GPCRs and RAS-related molecules.”
Read More »“This extensive immune cross-reactivity between SARS-CoV-2 antibodies and different antigen groups may play a role in the multi-system disease process of COVID-19, influence the severity of the disease, precipitate the onset of autoimmunity in susceptible subgroups, and potentially exacerbate autoimmunity in subjects that have pre-existing autoimmune diseases.”
Read More »Nature magazine addresses what scientists are discovering about the evolutionary battle COVID is undergoing inside our bodies. Throughout the course of a chronic SARS-CoV-2 infection, the virus might be evolving into dangerous new variants.
Read More »Topline results of a recent clinical trial showed that infliximab or abatacept “substantially improve[ed] clinical status and reduc[ed] deaths” in adult patients hospitalized with severe COVID-19. These drugs are often used to treat certain autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ankylosing spondylitis.
Read More »